IN THE KNOW
Resources.
-
- Client news
- FDA approves new preventive treatment for rare hereditary disease.
- The U.S. Food and Drug Administration (FDA) recently approved Takhzyro (lanadelumab-flyo) as the first preventive monoclonal antibody to treat hereditary angioedema (HAE) to help prevent attacks in patients 12 years and older. HAE is a rare and potentially life-threatening genetic disease that can cause unpredictable, debilitating episodes of painful swelling in the limbs, abdomen and airway.
- READ MORE
-
- Client news
- Moving toward performance-based networks.
- MedImpact discusses trends in value-based pharmacy reimbursement in Chain Drugstore Daily
- READ MORE
We are the PBM that puts clients and consumers first. Always. Ready for a change?
